Alpha Tau Medical Ltd. has received FDA approval for an Investigational Device Exemption $(IDE)$ to initiate a pilot study of its Alpha DaRT technology for patients with locally recurrent prostate cancer. This marks the company's fifth active IDE in the United States. The clinical trial will enroll up to 12 U.S. patients to primarily evaluate the safety of the treatment, with secondary objectives assessing efficacy through biochemical and clinical measures of disease progression and overall survival. No funding or grant from other organizations was mentioned.